文献速递前列腺癌

GBX2甲基化是新型预后生物标志物,可改善对导管内癌和筛状结构阴性前列腺癌患者生化复发的预测

GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
PubMed 文献 · Eur Urol Oncol · 2018-09-01

研究通过全基因组甲基化谱发现GBX2甲基化在GG4肿瘤中高于GG1,并在TCGA数据(n=478)和根治性前列腺切除术样本(n=254)中验证其预后价值。GBX2甲基化与Gleason评分、病理分期和生化复发相关,是生化复发的独立预测因子,在导管内癌/筛状结构阴性患者中可改善生化复发预测。TET2缺失导致前列腺细胞中GBX2甲基化增加。

要点

  • GBX2甲基化与Gleason评分(p<0.05)、病理分期(p<0.01)和生化复发(p<0.05)相关。
  • GBX2甲基化(p=0.004)是生化复发的独立预测因子。
  • 在导管内癌/筛状结构阴性患者中,GBX2甲基化改善生化复发预测(p=0.002)。

核心结论

  • GBX2甲基化是前列腺癌的新型预后因素和生化复发的独立预测因子。
  • 在导管内癌/筛状结构阴性患者中,GBX2甲基化对生化复发预测具有附加价值。
  • TET2缺失导致前列腺细胞中GBX2甲基化增加,揭示TET2介导的上游表观遗传调控机制。

研究设计与样本

  • 利用全基因组甲基化谱在发现队列中比较GG4与GG1肿瘤的GBX2甲基化水平。
  • 利用癌症基因组图谱数据(n=478)和根治性前列腺切除术样本(n=254)的定量甲基化检测进行验证。
  • 在前列腺细胞中使用甲基化CpG结合域测序和TET2功能敲除的甲基化分析研究GBX2甲基化调控。

主要发现

  • GBX2甲基化与Gleason评分(p<0.05)、病理分期(p<0.01)和生化复发(p<0.05)相关。
  • GBX2甲基化(p=0.004)、Gleason评分(p<0.001)、病理分期(p=0.012)和前列腺特异性抗原(p=0.005)是生化复发的独立预测因子。
  • 在导管内癌/筛状结构阴性患者中,GBX2甲基化改善生化复发预测(p=0.002)。
  • 前列腺细胞中TET2缺失导致GBX2甲基化增加。

关键数值与推荐

  • GBX2甲基化与Gleason评分相关(p<0.05)。
  • GBX2甲基化与病理分期相关(p<0.01)。
  • GBX2甲基化与生化复发相关(p<0.05)。
  • GBX2甲基化是生化复发的独立预测因子(p=0.004)。
  • 在导管内癌/筛状结构阴性患者中,GBX2甲基化改善生化复发预测(p=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor intraductal carcinoma/cribriform architecture (IDC/C) is associated with an unfavorable prognosis and biochemical recurrence (BCR) in prostate cancer (PCa). Up to 70% of PCa patients are IDC/C-negative, but it is estimated that 20% of these cases still experience BCR. Thus, biomarkers for better detection of aggressive disease in IDC/C-negative patients are required. OBJECTIVE: To investigate tumor-specific methylation of the transcription factor GBX2 as a novel prognosticator and predictor of BCR in PCa patients stratified by histopathologic features including IDC/C. DESIGN, SETTING, AND PARTICIPANTS: Using genome-wide methylome profiling, we identified higher GBX2 methylation in grade group (GG) 4 tumors compared to GG1 (discovery cohort). The prognostic nature of GBX2 methylation was validated in silico using The Cancer Genome Atlas data (n=478) and a quantitative methylation assay for radical prostatectomy samples (n=254). Regulation of GBX2 methylation was investigated in prostate cells using methyl-CpG-binding domain sequencing and methylation analysis in functional knockouts of TET2, a key epigenetic player in prostate carcinogenesis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The association of GBX2 methylation with Gleason score (GS), pathologic stage (pT), IDC/C, and BCR was analyzed using Kruskal-Wallis and Mann-Whitney tests. Univariate and multivariate Cox regression analyses were used to predict BCR. RESULTS: GBX2 methylation was associated with GS (p<0.05), pT (p<0.01), and BCR (p<0.05). GBX2 methylation (p=0.004), GS (p<0.001), pT (p=0.012), and prostate-specific antigen (p=0.005) were independent predictors of BCR. Among IDC/C-negative patients, GBX2 methylation improved prediction of BCR (p=0.002). Loss of TET2 in prostate cells resulted in greater GBX2 methylation. CONCLUSIONS: We identified GBX2 methylation as a novel prognostic factor in PCa and an independent predictor of BCR. We demonstrated the additive value of GBX2 methylation in predicting BCR among IDC/C-negative patients and elucidated a novel TET2-mediated upstream epigenetic regulatory mechanism of GBX2. PATIENT SUMMARY: We identified GBX2 methylation as a promising prognostic biomarker that could improve the identification of prostate cancer patients at higher risk of biochemical recurrence.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Jeyapala R, Savio AJ, Olkhov-Mitsel E, et al. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture. Eur Urol Oncol. 2018. PMID: 31200836. doi:10.1016/j.euo.2018.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。